Polaris AI Pharma Corp
041910
Company Profile
Business description
Polaris AI Pharma Corp is engaged in the production of raw pharmaceutical ingredients. It focuses on generic drugs and produces about 40 types of raw medicines, including asthma treatments, gastric ulcer treatments, and alcohol dependence treatments, and supplies them domestically and internationally.
Contact
25 Balangongdan-ro, Hyangnam-eup
Gyeonggi-do
Hwaseong-si
KORT: +82 318314800
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
164
Stocks News & Analysis
stocks
Is this still an ASX share to own forever?
Find out how this defensive player has fared after earnings.
stocks
After earnings, is Nvidia stock a buy, a sell, or fairly valued?
No signs of a slowdown in demand for Nvidia’s chips, and the long-term picture looks bright.
stocks
Short-term pain for long-term gain for undervalued ASX share
Cost reductions lower our profit estimates but should lead to improved long-term outcomes.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,077.60 | 37.40 | 0.41% |
| CAC 40 | 7,719.71 | 65.46 | 0.86% |
| DAX 40 | 23,594.80 | 107.47 | 0.46% |
| Dow JONES (US) | 45,271.23 | 24.58 | -0.05% |
| FTSE 100 | 9,177.99 | 61.30 | 0.67% |
| HKSE | 25,043.47 | 299.96 | -1.18% |
| NASDAQ | 21,497.73 | 218.10 | 1.02% |
| Nikkei 225 | 42,456.16 | 517.27 | 1.23% |
| NZX 50 Index | 13,128.19 | 53.38 | 0.41% |
| S&P 500 | 6,448.26 | 32.72 | 0.51% |
| S&P/ASX 200 | 8,809.90 | 42.60 | 0.49% |
| SSE Composite Index | 3,743.55 | 70.01 | -1.84% |